Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab: Blood Cancer Journal

M. Gentile, E.A. Martino, A. Visentin, M. Coscia, G. Reda, P. Sportoletti, F.R. Mauro, L. Laurenti, M. Varettoni, R. Murru, A. Chiarenza, E. Vigna, F. Mendicino, E. Lucia, S. Bossio, A.G. Recchia, R. Moia, D. Pietrasanta, G. Loseto, U. ConsoliI. Scortechini, F.M. Rossi, A. Zucchetto, H. Al-Janazreh, C. Vitale, G. Tripepi, G. D’Arrigo, I. Angeletti, R. Bomben, A. Neri, G. Cutrona, G. Fronza, F. Di Raimondo, G. Gaidano, A. Cuneo, R. Foà, M. Ferrarini, L. Trentin, V. Gattei, F. Morabito

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article number92
Number of pages3
JournalBlood Cancer J.
Volume10
Issue number9
DOIs
Publication statusPublished - 2020

Keywords

  • B lymphocyte receptor
  • idelalisib
  • rituximab
  • allogeneic stem cell transplantation
  • cancer growth
  • cancer staging
  • chronic lymphatic leukemia
  • clinical outcome
  • follow up
  • human
  • Letter
  • multivariate logistic regression analysis
  • overall survival
  • patient coding
  • predictive value
  • risk algorithm
  • scoring system
  • survival analysis
  • univariate analysis
  • validation study

Cite this